X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with NESCO LIMITED - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs NESCO LIMITED - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES NESCO LIMITED INDOCO REMEDIES/
NESCO LIMITED
 
P/E (TTM) x 31.6 26.6 118.8% View Chart
P/BV x 3.8 7.7 48.9% View Chart
Dividend Yield % 0.6 1.1 54.5%  

Financials

 INDOCO REMEDIES   NESCO LIMITED
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
NESCO LIMITED
Mar-15
INDOCO REMEDIES/
NESCO LIMITED
5-Yr Chart
Click to enlarge
High Rs3601,744 20.7%   
Low Rs2491,496 16.6%   
Sales per share (Unadj.) Rs119.0136.9 86.9%  
Earnings per share (Unadj.) Rs8.479.2 10.6%  
Cash flow per share (Unadj.) Rs15.284.0 18.1%  
Dividends per share (Unadj.) Rs1.606.50 24.6%  
Dividend yield (eoy) %0.50.4 130.9%  
Book value per share (Unadj.) Rs70.7383.0 18.5%  
Shares outstanding (eoy) m92.1514.09 654.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.611.8 21.6%   
Avg P/E ratio x36.420.4 178.2%  
P/CF ratio (eoy) x20.019.3 103.7%  
Price / Book Value ratio x4.34.2 101.9%  
Dividend payout %19.18.2 233.2%   
Avg Mkt Cap Rs m28,08322,827 123.0%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,16771 3,047.4%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,9681,929 568.5%  
Other income Rs m40286 13.9%   
Total revenues Rs m11,0072,215 496.9%   
Gross profit Rs m1,5651,380 113.4%  
Depreciation Rs m63367 944.5%   
Interest Rs m621 4,776.9%   
Profit before tax Rs m9091,598 56.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139481 28.8%   
Profit after tax Rs m7711,116 69.0%  
Gross profit margin %14.371.5 19.9%  
Effective tax rate %15.330.1 50.6%   
Net profit margin %7.057.9 12.1%  
BALANCE SHEET DATA
Current assets Rs m5,7254,153 137.9%   
Current liabilities Rs m5,454474 1,151.5%   
Net working cap to sales %2.5190.7 1.3%  
Current ratio x1.08.8 12.0%  
Inventory Days Days6215 427.1%  
Debtors Days Days7220 353.6%  
Net fixed assets Rs m5,3072,590 204.9%   
Share capital Rs m184141 130.8%   
"Free" reserves Rs m6,3315,187 122.1%   
Net worth Rs m6,5165,397 120.7%   
Long term debt Rs m1,3230-   
Total assets Rs m11,9706,763 177.0%  
Interest coverage x15.61,230.0 1.3%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.3 321.2%   
Return on assets %7.016.5 42.1%  
Return on equity %11.820.7 57.2%  
Return on capital %12.429.6 41.8%  
Exports to sales %00.3 0.0%   
Imports to sales %00.1 0.0%   
Exports (fob) Rs mNA5 0.0%   
Imports (cif) Rs mNA1 0.0%   
Fx inflow Rs m4,5075 83,616.0%   
Fx outflow Rs m1,1413 33,769.2%   
Net fx Rs m3,3662 167,437.8%   
CASH FLOW
From Operations Rs m8861,026 86.4%  
From Investments Rs m-1,706-914 186.7%  
From Financial Activity Rs m1,316-109 -1,212.6%  
Net Cashflow Rs m4974 12,112.2%  

Share Holding

Indian Promoters % 59.2 61.8 95.8%  
Foreign collaborators % 0.0 1.8 -  
Indian inst/Mut Fund % 12.5 4.9 255.1%  
FIIs % 6.0 8.7 69.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 22.9 97.8%  
Shareholders   12,805 12,392 103.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   THOMAS COOK INDIA  BAJAJ FINANCE  JSW HOLDINGS  TIL LTD  IL&FS INV. MANAGERS  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Feb 16, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - COMMEX TECHNOLOGY COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS